Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
JIANGSU, China, August 22, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…